shelf(0)

No. 051 · Combos · Peptide Blend

CJC-1295 DAC + Ipamorelin

— Not ranked · combination how tiers work →
  • Not approved as a combo
  • WADA ✗ S2
Compare Cite
Fingerprint combination
CJC-1295 DAC + Ipamorelin (no defined sequence)

Combos are blends of separate compounds, so there is no single sequence. This ring motif is decorative — open a component for its fingerprint.

01

Quick answers

What is CJC-1295 DAC + Ipamorelin?
One of the most popular GH secretagogue stacks, combining a long-acting GHRH analog with a selective GHRP for sustained, synergistic growth hormone elevation. CJC-1295 with DAC (long-acting GHRH analogue) plus ipamorelin (ghrelin-receptor agonist).
What is in CJC-1295 DAC + Ipamorelin?
CJC-1295 DAC + Ipamorelin typically combines CJC-1295 (with DAC) and Ipamorelin. Commercial products vary.
How strong is the evidence for CJC-1295 DAC + Ipamorelin?
It is not ranked. A PubMed search found no published studies of this combination; only reviews mention it. CJC-1295 (with DAC) and ipamorelin each have small human pharmacology studies.
Is CJC-1295 DAC + Ipamorelin FDA-approved?
No. CJC-1295 DAC + Ipamorelin is not an approved product; no regulator has reviewed the combination.
Is CJC-1295 DAC + Ipamorelin banned in sport?
Yes. CJC-1295 DAC + Ipamorelin is prohibited in sport by the World Anti-Doping Agency under S2 (peptide hormones, growth factors, related substances and mimetics).
How does CJC-1295 DAC + Ipamorelin work?
This blend exploits synergy between GHRH and GHRP pathways. CJC-1295 DAC activates the GHRH receptor via cAMP/PKA signaling for sustained GH release (half-life 6-8 days due to albumin binding), while ipamorelin activates the ghrelin receptor (GHS-R1a) via IP3/PKC.
What is known about the safety of CJC-1295 DAC + Ipamorelin?
Both components have individual clinical trial data. Common side effects: water retention, tingling, headache, flushing.

Last reviewed · editorial policy · markdown

02

Evidence

  1. D In vitro
  2. C Animal
  3. B Human pilot
  4. A RCT
  5. S Approved

Not ranked: combinations have no published studies of their own. See the components below.

A PubMed search found no published studies of this combination; only reviews mention it. CJC-1295 (with DAC) and ipamorelin each have small human pharmacology studies.

Tiers rate the strength of published evidence — not effectiveness, safety, or a recommendation.

03

At a glance

Routes studied
Subcutaneous, Intramuscular Routes used in published research
FDA
Not approved as a combination
WADA
Prohibited · S2 Peptide hormones, growth factors, related substances and mimetics
04

Overview

One of the most popular GH secretagogue stacks, combining a long-acting GHRH analog with a selective GHRP for sustained, synergistic growth hormone elevation.

Research status No published studies of the combination; CJC-1295 (DAC) has a randomized dose-escalation trial in healthy adults and ipamorelin has small human pharmacokinetic studies

05

Mechanism

This blend exploits synergy between GHRH and GHRP pathways. CJC-1295 DAC activates the GHRH receptor via cAMP/PKA signaling for sustained GH release (half-life 6-8 days due to albumin binding), while ipamorelin activates the ghrelin receptor (GHS-R1a) via IP3/PKC. Together they produce amplified GH pulses exceeding either component alone.

06

Effects reported in research

These outcomes are attributed to the individual components. The combination itself has not been studied.

  • Sustained and amplified GH release
  • Improved body composition and fat loss
  • Enhanced deep sleep and recovery
  • Increased IGF-1 levels
07

Safety & unknowns

Both components have individual clinical trial data. Common side effects: water retention, tingling, headache, flushing. CJC-1295 DAC provides sustained GH elevation which may increase IGF-1 beyond physiological levels. Ipamorelin adds minimal cortisol/prolactin risk. Not FDA-approved as a combination.

Unknowns. The combination itself has not been studied; interactions between its components are unknown.

Informational only — not medical advice. peptidemeta publishes no dosing, protocols, or sourcing. Talk to a qualified clinician about any treatment decision.

08

Studies [2]

  1. Clinical trial 2006

    Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

    Teichman SL, Neale A, Lawrence B, et al. Journal of Clinical Endocrinology and Metabolism

    Two randomized placebo-controlled ascending-dose trials of the CJC-1295 (DAC) component in healthy adults: a single injection raised GH 2- to 10-fold for 6 days or more and IGF-I for 9–11 days (half-life 5.8–8.1 days).

    [pubmed] [doi]

  2. Preclinical 1998

    Ipamorelin, the first selective growth hormone secretagogue

    Raun K, Hansen BS, Johansen NL, et al. European Journal of Endocrinology

    Rat and swine study on the ipamorelin component: it released GH as effectively as GHRP-6 but, unlike GHRP-6 and GHRP-2, did not raise ACTH or cortisol.

    [pubmed] [doi]

09

Components

CJC-1295 (with DAC) Tier A · Controlled human trials A Ipamorelin Tier A · Controlled human trials A
11

Status sources

Sources behind the tier, regulatory status, sequence and dates on this page.

12

Cite this entry

$ cite --format=apa

peptidemeta. (2026). CJC-1295 DAC + Ipamorelin. In peptidemeta: The peptide library, ranked by evidence. Retrieved November 8, 2026, from https://peptidemeta.com/p/cjc-1295-dac-ipamorelin/

$ cite --format=bibtex 
@misc{peptidemeta-cjc-1295-dac-ipamorelin,
  title = {CJC-1295 DAC + Ipamorelin},
  author = {{peptidemeta}},
  year = {2026},
  howpublished = {\url{https://peptidemeta.com/p/cjc-1295-dac-ipamorelin/}},
  note = {Accessed 2026-11-08}
}

Accessed date reflects when you opened this page. Cite primary studies for scientific claims.

esc
↑↓ navigate ↵ open